Quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).

Lexington, US
98 (est)+2%

Key People at Quanterix

Paul M. Meister

Paul M. Meister

David Duffy, Ph.D.

David Duffy, Ph.D.

CTO & VP, Research
Paul Chapman

Paul Chapman

President & CEO & Board Director
Julien Bradley

Julien Bradley

Senior Director, Sales & Marketing
David H. Wilson

David H. Wilson

VP, Product Development
James Drummey

James Drummey

Senior Director, Manufacturing Operations

Quanterix Locations

Lexington, US
San Francisco, US
San Diego, US
Boston, US
Austin, US
Philadelphia, US
New York, US
Baltimore, US

Quanterix Metrics

Quanterix Summary

Founding Date


Total Funding

$69.5 M

Latest funding size

$46 M

Time since last funding

7 months


Bain Capital Ventures, In-Q-Tel, Flagship Ventures, ARCH Venture Partners, Bain Capital Ventures, ARCH Venture Partners, Cormorant Asset Management, ARCH Overage Fund, Trinitas Capital, Tufts University

Quanterix Online Presence

Quanterix Company Life